BCPCBalchem Corp
The Read
1% after record $1B sales and new institutional investment boosted growth optimism, then fell about 7.
The schedule
- Fri23Oct
Balchem’s Q3 2026 results and guidance update, where investors will judge whether double‑digit growth and margin expansion can sustain a mid‑30s earnings multiple near recent highs.
- Fri20Nov
Management commentary around new product launches and penetration in human and animal nutrition channels, likely via conferences or investor outreach post‑Q3 earnings.
- Tue12Jan
Winter‑season commentary from suppliers and customers on feedstock costs and the extent to which Balchem can continue to pass through inflation without eroding volumes.
- Tue9Feb
Full‑year 2026 results and initial 2027 guidance, a key checkpoint on Balchem’s ability to sustain double‑digit growth and high returns while funding elevated capex.
- Thu29Apr
First‑quarter 2027 results that will test whether Balchem is tracking its newly issued annual guidance and maintaining pricing power in specialty nutrition and chemicals.
- Fri30Jul
Mid‑year 2027 results where Balchem’s execution on growth initiatives and margin resilience in human and animal nutrition will be reassessed against a potentially maturing cycle.
Past
- Tue15Sep
Macro and industry updates on ag, petrochemical, and logistics costs that will influence Balchem’s specialty nutrition and chemical margins ahead of Q3 earnings.
- Fri31Jul
Actual outcome: Bull · $178.00 at outcome
Balchem delivered strong Q2 results, highlighted by broad-based revenue growth across all segments, including a 15% increase in Animal Nutrition & Health. The company surpassed revenue consensus by $15 million and posted an adjusted EPS beat, demonstrating the pricing power needed to protect margins and driving shares past the bull target.
The Q2 print must demonstrate pricing power to protect margins. A strong beat could push shares toward $172.50, while unmitigated cost pressures or soft guidance would risk a rapid contraction to $154.00.
- Thu30Apr
Actual outcome: Bear · $161.52 at outcome
Balchem reported Q1 2026 EPS of $1.22, exactly in line with consensus estimates. Failing to deliver the clean beat and strong growth metrics required to justify its premium 36.5x P/E multiple, the stock experienced a valuation reset, dropping 7.8% to close well below the $166 bear floor.
- Mon2Mar
Actual outcome: Bull · $174.50 at outcome
Balchem met Q4 EPS estimates of $1.22 while achieving a major milestone of record $1 billion in annual sales, which offset concerns regarding its valuation premium. The stock's rally past the bull target was driven by positive sentiment following a new $18 million institutional investment from Harvey Partners and the launch of the Metalosate T.E.A.M. digital platform, signaling robust growth and innovation across its nutrition segments.
- Fri20Feb
Actual outcome: Bull · $175.68 at outcome
Price reached or exceeded bull target ($178.00) at outcome date.